- The P-II CONVEY withdrawal study evaluates efficacy & safety of vixotrigine (200/350 mg, bid) vs PBO in 265 patients with SFN for 12wks.
- The study met its 1EPs i.e., 200mg dose showed a reduction in mean ADP & worst daily pain score @12wks. while 350mg dose did not meet its 1EPs of mean change in ADP but met statistical significance in PGIC
- The 2EPs of both doses include a proportion of patients with ≥2-point or improvement in ADP scores with ≥a 30% reduction in ADP @12wks. but the therapy was well-tolerated. The company plan to start a P-III trial based on data from a vixotrigine program
Click here to read full press release/ article | Ref: Biogen | Image: The Business Journals